IPP Bureau
Adare Pharma divests Adare Biome to dsm-firmenich
By IPP Bureau - July 04, 2023
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
SHL Medical acquires 100% of the shares in LCA Automation
By IPP Bureau - July 04, 2023
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules
By IPP Bureau - July 04, 2023
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24
By IPP Bureau - July 03, 2023
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Granules India successfully completes Two US FDA Audits in a span of 2 weeks
By IPP Bureau - July 03, 2023
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
Annovis’ Buntanetap in PD faces complex road ahead despite phase III progress, says GlobalData
By IPP Bureau - July 03, 2023
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030
By IPP Bureau - July 03, 2023
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
VitaDAO launches VITA-FAST tokens, revolutionizing governance in longevity research
By IPP Bureau - July 03, 2023
The VITA-FAST tokens have been met with overwhelming interest
Merck to expand reagent production capacity in China
By IPP Bureau - June 30, 2023
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
ENPICOM secures extended financing from current investors
By IPP Bureau - June 30, 2023
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program
By IPP Bureau - June 30, 2023
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Shilpa Medicare launches Lenvatinib Capsules in India under the brand name Lenshil
By IPP Bureau - June 30, 2023
The company is already marketing the 4 mg and 10 mg strengths
Rystiggo needs marketing strategy to fully compete in myasthenia gravis space, says GlobalData
By IPP Bureau - June 30, 2023
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
GenWorks Health launches IVD tests for dengue and malaria
By IPP Bureau - June 29, 2023
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
Granules India and Central Bureau of Narcotics unite to tackle drug abuse
By IPP Bureau - June 29, 2023
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
